SequelSEC

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Biological Products, (No Diagnostic Substances) · CIK 0001425205 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$324.97M
Fiscal year ended 2026-06-30
Operating income
-$301.31M
Fiscal year ended 2026-06-30
Free cash flow
-$296.40M
Fiscal year ended 2026-06-30

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported revenue of $324.97M and net income of -$289.52M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from IOVANCE BIOTHERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

IOVANCE BIOTHERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$324.97M
Cost of revenue$167.68M
Gross profit$157.29M
Operating income-$301.31M
Net income-$289.52M
Research & development$267.72M
Weighted-average diluted sharesUnavailable
Pretax income-$293.78M
Income tax expense-$4.26M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$149.18M
Selling & marketingUnavailable

Balance

IOVANCE BIOTHERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$110.77M
Total assets$915.53M
Current assets$464.26M
Total liabilities$179.49M
Current liabilities$106.85M
Total equity incl. NCI$736.04M
Temporary (mezzanine) equityUnavailable
Inventory$55.59M
Accounts receivable$102.12M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$26.21M

Cash flow

IOVANCE BIOTHERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$264.18M
Capital expenditures$32.21M
Investing cash flow-$44.87M
Financing cash flow$287.85M
Net change in cash-$21.64M
Stock-based compensation$46.72M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$30.85M

Derived

IOVANCE BIOTHERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$296.40M
Gross margin48.4%
Operating margin-92.7%
FCF margin-91.2%
SBC / revenue14.4%
Current ratio4.35x
Revenue YoY growthUnavailable
Net margin-89.1%
R&D / revenue82.4%
CapEx / revenue9.9%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IOVA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.